Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 8Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 281Carcinoma, Non-Small-Cell Lung 251Leukemia, Myeloid, Acute 189Breast Neoplasms 151Melanoma 150Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 113Lymphoma 112Leukemia, Lymphocytic, Chronic, B-Cell 107Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 85Prostatic Neoplasms 83Lung Neoplasms 81Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 67Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 49

Interventions

Thiotepa 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Busulfan 1Bone Marrow Transplantation 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Teratoma × Clear all
NCT00003926 2017-11-29

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
13 enrolled
CNSGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcoma

Ovarian Germ Cell Cancer, Astrocytoma, Brain Neoplasms, Chordoma, Ependymoma, Glioma, Kidney Neoplasms, Liver Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Hepatoblastoma, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡